扶正化瘀片基于miR-122/IL-10因子治疗肝纤维化
|
摘要
目的:探讨扶正化瘀片对肝纤维化患者的软坚散结作用,是否与miR-122/白细胞介素-10(interleukin-10,IL-10)通路调节作用有关。方法:慢性肝炎肝纤维化患者75例,随机分为观察组41例和对照组34例,另留取健康体检者30例为健康组。对照组给予恩替卡韦治疗,观察组给予恩替卡韦联合扶正化瘀片抗纤维化联合治疗。治疗前后同时测定各组血清中miR-122与IL-10mRNA的表达,采用ELISA法测定肝细胞超氧化物歧化酶(superoxide orgotein dismutase,SOD)、活性氧(reactive oxygen species,ROS)活性,结合临床肝纤维化四项[Ⅲ型前胶原氨端肽(procollagenⅢ,PCⅢNP)、IV型胶原(collagenⅣ,CIV)、透明质酸(hyaluronic acid,HA)、层粘连蛋白(laminin,LN)]以及常规病理评价。结果:进行Ishak纤维化评分结果发现,治疗前对照组、观察组平均为5.5分;治疗后对照组平均为5.1分,观察组为3.5分,两组比较,差异有统计学意义(P<0.05)。观察组肝纤维化CIV、HA较对照组明显下降,两组比较,差异有统计学意义(P<0.05)。观察组治疗后IL-10与对照组比较,差异有统计学意义(P<0.05)。观察组治疗后ROS较对照组明显下降(P<0.05),SOD较对照组明显上升(P<0.05)。结论:扶正化瘀片可以调节miR-122/IL-10,从而控制患者的肝纤维化进展,具有明显调节作用。
Objective:To investigate the softening and dispersing effect of Fuzheng Huayu Tablet combined with antiviral therapy on hepatic fibrosis patients,and whether it is related to the regulation of miR1-22/IL-10 pathway.Methods:75 patients with chronic hepatitis and hepatic fibrosis were randomly divided into an experimental group(45 cases) and a control group(30 cases),and 30 healthy persons were selected as the healthy group.The control group received antiviral treatment and protective liver cell therapy according to clinical routine.The experimental group was given the Fuzheng Huayu tablet 1.5 g/times,and 3 times a day for 48 weeks.Before and after treatment were measured serum miR-122 and interleukin(IL-10) mRNA expression,ELISA liver cell Superoxide dismutase(SOD),Reactive oxygen species(ROS)activity,combined with clinical liver fibrosis four(PCIIINP,CIV,HA,LN) and pathological evaluation.Results:The Ishak fibrosis score suggests that before treatment the control group and the experimental group averaged 5.5 points.After treatment the control group had an average of 5.1 points,the experimental group was 3.5 points,and the statistical comparison between the two groups showed significant difference(P<0.05).The liver fibrosis CIV and HA in the experimental group were lower in the control group,and there was a significant difference between the groups(P<0.05).The IL-10 in the experimental group was significantly different from that in the control group(P<0.05).After treatment in the experimental group ROS was significantly lower than that in the control group(P<0.05),and SOD increased significantly in the control group(P<0.05).Conclusion:Fuzheng Huayu Tablet can regulate miR-122/IL-10,and can control the progression of hepatic fibrosis in patients,with significant biological regulation effect.
Objective:To investigate the softening and dispersing effect of Fuzheng Huayu Tablet combined with antiviral therapy on hepatic fibrosis patients,and whether it is related to the regulation of miR1-22/IL-10 pathway.Methods:75 patients with chronic hepatitis and hepatic fibrosis were randomly divided into an experimental group(45 cases) and a control group(30 cases),and 30 healthy persons were selected as the healthy group.The control group received antiviral treatment and protective liver cell therapy according to clinical routine.The experimental group was given the Fuzheng Huayu tablet 1.5 g/times,and 3 times a day for 48 weeks.Before and after treatment were measured serum miR-122 and interleukin(IL-10) mRNA expression,ELISA liver cell Superoxide dismutase(SOD),Reactive oxygen species(ROS)activity,combined with clinical liver fibrosis four(PCIIINP,CIV,HA,LN) and pathological evaluation.Results:The Ishak fibrosis score suggests that before treatment the control group and the experimental group averaged 5.5 points.After treatment the control group had an average of 5.1 points,the experimental group was 3.5 points,and the statistical comparison between the two groups showed significant difference(P<0.05).The liver fibrosis CIV and HA in the experimental group were lower in the control group,and there was a significant difference between the groups(P<0.05).The IL-10 in the experimental group was significantly different from that in the control group(P<0.05).After treatment in the experimental group ROS was significantly lower than that in the control group(P<0.05),and SOD increased significantly in the control group(P<0.05).Conclusion:Fuzheng Huayu Tablet can regulate miR-122/IL-10,and can control the progression of hepatic fibrosis in patients,with significant biological regulation effect.
引文
[1]张巍,郑欢伟,刘彦华,等.活血清肝煎剂预防慢性乙型肝炎肝硬变结节性增生癌变效果观察[J].中华中医药学刊,2015,33(8):1894-1896.
[2]胡晓云,刘智泓,孙剑.《2015年世界卫生组织慢性乙型肝炎病毒感染预防、关怀和治疗指南》解读:无创肝纤维化评估、抗病毒治疗策略和国家防治计划实施[J].临床肝胆病杂志,2015,31(6):829-832.
[3]GAMAL S M,SHIV K,SARIN A,et al.Liver fibrosis:consensus recommendations of the Asian Pacific Association for the Study of the Liver(APASL)[J].Hepatol Int,2012(3):323-333.
[4]南月敏,蒋树林,姚希贤,等.肝硬化病理与发病机制[J].中国全科医学,2013,5(6):364-365.
[5]中国中西医结合学会肝病专业委员会.肝纤维化中西医结合诊疗指南[J].中西医结合肝病杂志,2010,2(4):54-58.
[6]高冲,刘璐,胡爱菊,等.活血化瘀中药的药理作用研究进展[J].药物评价研究,2013,36(1):64-68.
[7]陈文龙,曹文富,李强,等.益气化瘀化痰养阴方对肝纤维化大鼠PPARγ与DLK1的影响[J].中成药,2015,37(1):28-34.
[8]LEROY V,HILLERET M N,STURM N,et al.Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C[J].J Hepatol,2007,46(5):775-782.
[9]ZHUANG C,LI X,ZHAO J,et al.Stability and mechanical properties of BC(x) crystals:the role of B-B bonds and boron concentration[J].J Phys Condens Matter,2010;22(21):1245-1250.
[10]赵韦,赵志敏,王峥涛,等.活血化瘀类方抗肝纤维化疗效比较[J].中药药理与临床,2012,28(3):15-18.
[11]权志镇.香菇多糖联合治疗食管静脉曲张破裂出血[J].中华消化内镜杂志,2014,17(4):222-223.
[12]甘天福,张光曙.548例代偿期肝硬化临床与病理研究[J].实用医药杂志,2012;19(1):7-9.
[2]胡晓云,刘智泓,孙剑.《2015年世界卫生组织慢性乙型肝炎病毒感染预防、关怀和治疗指南》解读:无创肝纤维化评估、抗病毒治疗策略和国家防治计划实施[J].临床肝胆病杂志,2015,31(6):829-832.
[3]GAMAL S M,SHIV K,SARIN A,et al.Liver fibrosis:consensus recommendations of the Asian Pacific Association for the Study of the Liver(APASL)[J].Hepatol Int,2012(3):323-333.
[4]南月敏,蒋树林,姚希贤,等.肝硬化病理与发病机制[J].中国全科医学,2013,5(6):364-365.
[5]中国中西医结合学会肝病专业委员会.肝纤维化中西医结合诊疗指南[J].中西医结合肝病杂志,2010,2(4):54-58.
[6]高冲,刘璐,胡爱菊,等.活血化瘀中药的药理作用研究进展[J].药物评价研究,2013,36(1):64-68.
[7]陈文龙,曹文富,李强,等.益气化瘀化痰养阴方对肝纤维化大鼠PPARγ与DLK1的影响[J].中成药,2015,37(1):28-34.
[8]LEROY V,HILLERET M N,STURM N,et al.Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C[J].J Hepatol,2007,46(5):775-782.
[9]ZHUANG C,LI X,ZHAO J,et al.Stability and mechanical properties of BC(x) crystals:the role of B-B bonds and boron concentration[J].J Phys Condens Matter,2010;22(21):1245-1250.
[10]赵韦,赵志敏,王峥涛,等.活血化瘀类方抗肝纤维化疗效比较[J].中药药理与临床,2012,28(3):15-18.
[11]权志镇.香菇多糖联合治疗食管静脉曲张破裂出血[J].中华消化内镜杂志,2014,17(4):222-223.
[12]甘天福,张光曙.548例代偿期肝硬化临床与病理研究[J].实用医药杂志,2012;19(1):7-9.